Evaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Primary objective
- To assess wound healing and granulation tissue formation when using the NPWT system
Secondary objectives
- To investigate the pain level at dressing removal
- To visually check exudate removal
- To investigate the ease of use for the subject and care giver when using the NPWT system
| Condition | Intervention |
|---|---|
|
Diabetes Foot Ulcers |
Procedure: NPWT System Device: NPWT system |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Prospective, Open, Non-controlled Clinical Investigation to Evaluate a NPWT (Negative Pressure Wound Therapy) System to be Used in the Treatment of Diabetic Foot Ulcers (DFUs) Including Post Amputation Wounds Associated With Diabetes. |
- Mean Change in Wound Area. [ Time Frame: From baseline to maximum 4 weeks ] [ Designated as safety issue: No ]Measured by tracing of wound and measured by planimeter.
| Enrollment: | 16 |
| Study Start Date: | January 2010 |
| Study Completion Date: | July 2010 |
| Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
NPWT system
Negative pressure wound therapy
|
Procedure: NPWT System
Dressing change 3 times per week
Device: NPWT system
3 dressing changes/week for maximum 4 weeks.
|
Detailed Description:
The investigation is designed as a prospective, open, non-controlled clinical investigation.
Wounds to be treated under this protocol should be Diabetic foot ulcers (DFUs) or post amputation wounds associated with diabetes in hospitalized subjects or subjects treated at home. One ulcer or post amputation wound per subject will be treated for a maximum duration of 4 weeks. All subjects will receive negative pressure treatment with the NPWT system, -120 mm Hg.
In total, 10-15 subjects at two sites will be enrolled provided that they fulfill all the inclusion criteria and none of the exclusion criteria and have signed and dated a written informed consent.
The subjects will be consecutively allocated to a specific subject identification code and the recruitment will be competitive.
The primary variable wound healing and granulation tissue formation will be assessed by digital planimeter, digital photography and visual estimation.
Pain level and subject/investigator convenience will be assessed by convenience surveys.
An evaluable subject is defined as a subject completing the investigation with 4 weeks of treatment, a subject healed before 4 weeks of treatment or if the investigator judge that the wound has adequately responded on NPWT before 4 weeks and that continued treatment can be made with alternative treatment.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diabetic foot ulcers (DFUs) including post amputation wounds associated with diabetes suitable for Negative Pressure Wound Therapy according to the investigator's judgment
- 1 cm2 ≤ Wound size ≤ 200 cm2
- Male or female, 18 years and above
- Signed Informed Consent Form
- Subject understands the written subject Information
Exclusion Criteria:
- Need for frequent dressing changes, i.e.<72 hours between the changes
- Dry wounds
- Critical ischemia (for wound healing) according to investigator's judgement
- Malignancy in the wound and/or wound margin
- Target ulcer previous not successfully treated with NPWT within 48 hours
- Poorly controlled diabetes according to investigators judgement.
- Osteomyelitis which has been left untreated
- Infection which has been left untreated
- Unexplored fistula
- > 10% surface area necrotic tissue with eschar present after debridement
- High risk for bleeding complications
- Exposed major blood vessels, organs or nerves
- Current or within 3 months treatment with chemotherapy or irradiation
- Known hypersensitivity to the dressing material
- Expected technically impossible to seal the film to maintain a vacuum for treatment
- Expected non compliance with the Clinical Investigation Plan
- Pregnancy
- Subjects not suitable for the investigation according to the investigator's judgement
- Subjects previously included in this investigation
- Subjects included in other ongoing clinical investigation at present or during the past 30 days
Contacts and Locations| United Kingdom | |
| Freeman Hospital | |
| Newcastle upon Tyne,, United Kingdom | |
| Norfolk & Norwich University Hospital | |
| Norfolk,, United Kingdom | |
| Principal Investigator: | Gerard Stansby, MD, Prof. | Freeman Hospital, Newcastle upon tyne |
More Information
No publications provided
| Responsible Party: | Molnlycke Health Care AB |
| ClinicalTrials.gov Identifier: | NCT01011387 History of Changes |
| Other Study ID Numbers: | NPWT 01 |
| Study First Received: | November 4, 2009 |
| Results First Received: | December 22, 2010 |
| Last Updated: | March 20, 2012 |
| Health Authority: | United Kingdom: National Health Service |
Keywords provided by Molnlycke Health Care AB:
|
Diabetic foot ulcers |
Additional relevant MeSH terms:
|
Diabetes Mellitus Ulcer Foot Ulcer Diabetic Foot Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Pathologic Processes Foot Diseases |
Skin Diseases Leg Ulcer Skin Ulcer Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Diabetes Complications Diabetic Neuropathies |
ClinicalTrials.gov processed this record on June 18, 2013